F. Hoffmann-La Roche Ltd. (Switzerland) and Danaher Corporation (US) are Leading Players in the Molecular Cytogenetics Market
The molecular cytogenetics market is valued at an estimated USD 3.1 billion in 2023 and is projected to reach USD 4.9 billion by 2028 at a CAGR of 9.9% during the forecast period. Growth in the molecular cytogenetics market is mainly driven by factors such as the rising incidence and prevalence of cancer & genetics disorders, growing usage of advanced technologies, and growing number cancer centers.
The key players in this market are Thermo Fisher Scientific Inc. (US), Illumina Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), Abbott Laboratories (US), Agilent Technologies, Inc. (US), Pacific Biosciences (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne Corporation (US), GeneDx (US), Oncocyte Corporation (US), BioView (Israel), Oxford Gene Technology IP, Limited. (UK), Applied Spectral Imaging, Inc. (US), Cyto-Test Inc. (US), KromaTiD, Inc. (US), Genial Genetic Solutions, Ltd. (UK), Cytognomix, Inc. (Canada), MetaSystems (Germany), SciGene (US), Biomodal (UK), Biocare Medical (US), BioDot (US), OncoDNA (Belgium).
To know about the assumptions considered for the study download the pdf brochure
In 2022, F. Hoffmann-La Roche Ltd. (Switzerland) held a significant market share in the molecular cytogenetics market. The company's prominent position stems from its strong worldwide sales and distribution network, effectively showcasing its products across diverse countries. Roche strategically prioritizes research endeavors to create innovative, superior offerings compared to competitors. Through investments in research, the company aims to enhance its product portfolio and allocate capital wisely, paving the way for future growth.
Furthermore, Roche implements both inorganic strategies, such as acquisition, to further strengthen its standing in the molecular cytogenetics market. In May 2021, Roche acquired GenMark to expand its portfolio of molecular cytogenetic products.
Danaher Corporation (US) maintained its dominant position in the molecular cytogenetics market in 2022. The company’s strong distribution networks spanning North America, Europe, and other developed countries have contributed to its sustained leadership in the market. The company employs inorganic growth strategies to enhance its market dominance, such as partnership. In April 2022, Danaher Corporation partnered with Duke University to form its first Danaher Beacon for Gene Therapy Innovation. These strategic initiatives enable Roche to secure a larger market share and strengthen its position in the molecular cytogenetics market.
Agilent Technologies, Inc. (US), a prominent player in the global molecular cytogenetics market, secured a significant market share in the molecular cytogenetics market in 2022. The company’s strong presence in the North America, Europe and Asia Pacific strenghthens its geographical reach. Agilent Technologies caters to a diverse customer base across various geographic locations. In addition to its R&D efforts and supply chain management, Agilent Technologies leverages organic and inorganic growth strategies to maintain its market leadership. For example, in March 2020, Agilent introduced three new microarrays for prenatal and postnatal research. Such developments contribute to the company’s continued success and its sustained leading position in the molecular cytogenetics market.
Related Reports:
Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization (Array-based, Standard)), Application (Cancer, Genetics Disorders) - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
